Special Issue

Unconventional Antiviral Agents

Message from the Guest Editors

The activity of current antiviral agents is limited to a few viruses, such as HIV, herpes viruses, HBV/HCV, and the influenza viruses. The available drugs target a limited number of viral steps, i.e., replication and transcription by inhibition of polymerases and integrases; protein maturation by targeting proteases; and entry, uncoating, and budding by modification or hindrance of virus attachment and surface proteins or cell receptors. While these activities effectively prevent/suppress viral replication, most of the time they do not eradicate the virus from the host, especially when chronic infections or latency are involved. Moreover, drug-resistant viruses, new virus variants, and new virus species that do not respond to any of the current antiviral treatments constantly emerge and are becoming an increasingly urgent priority. In this Special Issue, we aim to explore new ways to combat viral infections. In particular, we welcome research on new compounds with antiviral activity, with unconventional targets and mechanisms of action against all types of viruses.

Guest Editors

Prof. Dr. Sara N. Richter

Department of Molecular Medicine, University of Padua, Padua, Italy

Prof. Dr. Louis Flamand

Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine Laval University and Division of Infectious and Immune Diseases, CHU de Quebec Research Center-Université Laval, Quebec City, Canada

Deadline for manuscript submissions

closed (1 December 2020)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/40681

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).